Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study

References

• Cancer Society of New ZealandCancer statistics [webpage on the Internet]Wellington, NZCancer Society of New Zealand [updated February 21, 2011]. Available from: http://www.cancernz.org.nz/divisions/auckland/about/cancer-statisticsAccessed March 18, 2015
   Google Scholar
• Ministry of HealthCancer: new registrations and deaths 2011 [webpage on the Internet]Wellington, NZMinistry of Health2014 [updated October 14, 2014]. Available from: http://www.health.govt.nz/publication/cancer-new-registrations-and-deaths-2011Accessed March 18, 2015
   Google Scholar
• McKenzieFEllison-LoschmannLJeffreysMInvestigating reasons for socioeconomic inequalities in breast cancer survival in New ZealandCancer Epidemiol201034670270820696630
   PubMed Web of Science ®Google Scholar
• RocheData Sheet: Herceptin®Auckland, NZRoche Products (New Zealand) Ltd2014 Available from: http://www.medsafe.govt.nz/profs/datasheet/h/Herceptininf.pdfAccessed May 11, 2015
   Google Scholar
• KruseGBAmonkarMMSmithGSkoniecznyDCStavrakasSAnalysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a US populationJ Manag Care Pharm200814984485719006441
   PubMed Web of Science ®Google Scholar
• VesciaSBaumgärtnerAKJacobsVRManagement of venous port systems in oncology: a review of current evidenceAnn Oncol200819191517846025
   PubMed Web of Science ®Google Scholar
• PettengellRDaviesAJHarveyVJExperience with an implantable venous access system for chemotherapyN Z Med J19911049152842851852329
   PubMed Web of Science ®Google Scholar
• Launay-VacherVAn appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needsCancer Chemother Pharmacol20137261361136724057040
   PubMed Web of Science ®Google Scholar
• ShepardHMJinPSlamonDJPirotZManevalDCHerceptinChernajovskyYNissimATherapeutic AntibodiesBerlin, GermanySpringer-Verlag Berlin Heidelberg2008183219
   Google Scholar
• RocheData Sheet: Herceptin® SCAuckland, NZRoche Products (New Zealand) Ltd2014 Available from: http://www.medsafe.govt.nz/Profs/Datasheet/h/herceptinscinj.pdfAccessed May 11, 2015
   Google Scholar
• FrostGIRecombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administrationExpert Opin Drug Deliv20074442744017683255
   PubMed Web of Science ®Google Scholar
• BookbinderLHHoferAHallerMFA recombinant human enzyme for enhanced interstitial transport of therapeuticsJ Control Release2006114223024116876899
   PubMed Web of Science ®Google Scholar
• WynneCHarveyVSchwabeCWaakaDMcIntyreCBittnerBComparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancerJ Clin Pharmacol201353219220123436264
   PubMed Web of Science ®Google Scholar
• IsmaelGHeggRMuehlbauerSSubcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trialLancet Oncol201213986987822884505
   PubMed Web of Science ®Google Scholar
• Ministry of Health: Medical Oncology National Implementation Plan. 2012/13Wellington, NZMinistry of Health2012 [updated October 10, 2012. Available from: http://www.health.govt.nz/publication/medical-oncology-national-implementation-plan-2012-13Accessed March 18, 2015
   Google Scholar
• BurcombeRChanSSimcockRSamantaKPercivalFBarrett-LeePSubcutaneous trastuzumab (Herceptin®): A UK time and motion study in comparison with intravenous formulation for the treatment of patients with HER2-positive early breast cancerAdv Breast Can Res201324133140
   Google Scholar
• Pharmaceutical Management Agency (PHARMAC)Cost Resource ManualWellington, NZPHARMAC2014 Available from: http://www.pharmac.health.nz/assets/pfpa-v2-1-cost-resource-manual.pdfAccessed March 18, 2015
   Google Scholar
• De CockEKnoopAJakobsenEHManual injection of subcutaneous trastuzumab vs intravenous infusion for HER2-positive early breast cancer: a time-and-motion studyEuropean Cancer Congress 20132013 Sep 27–Oct 1Amsterdam, NL Abstract #P128
   Google Scholar
• PivotXGligorovJMüllerVPrefHer Study GroupPreference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised studyLancet Oncol2013141096297023965225
   PubMed Web of Science ®Google Scholar
• RuleSCollinsGPSamantaKSubcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United KingdomJ Med Econ201417745946824720836
   PubMedGoogle Scholar
• De CockEPanISandovalMMillarDKnoopAHealthcare professionals’ perceptions of the impact of switching from the intravenous to the subcutaneous formulation of trastuzumabNinth European Breast Cancer Conference2014 March 19–21Glasgow, Scotland Abstract#42
   Google Scholar
• National Institute for Health and Clinical Excellence: Infection: Prevention and Control of Healthcare-Associated Infections in Primary and Community CareClinical Guideline: Methods, Evidence and RecommendationsLondon, UKNational Clinical Guideline Centre2012 Available from: http://www.nice.org.uk/guidance/cg139/evidence/cg139-infection-control-full-guideline3Accessed March 18, 2015
   Google Scholar
• WilsonMPorterDJMaherASafety and efficacy of implanted central venous catheters during adjuvant treatment of breast cancer and in a general oncology population. American Society of Clinical Oncology 2011 Annual Meeting; Chicago, ILJ Clin Oncol20112915 Suppl Abstract # 9124.
   Web of Science ®Google Scholar
• BoersmaRSSchoutenHCClinical practices concerning central venous catheters in haematological patientsEur J Oncol Nurs201014320020420117964
   PubMed Web of Science ®Google Scholar
• RosenthalVDGuzmanSMigoneOCrnichCJThe attributable cost, length of hospital stay, and mortality of central line-associated bloodstream infection in intensive care departments in Argentina: A prospective, matched analysisAm J Infect Control200331847548014647110
   PubMed Web of Science ®Google Scholar
• WorthLJBrettJBullALMcBrydeESRussoPLRichardsMJImpact of revising the National Nosocomial Infection Surveillance System definition for catheter-related bloodstream infection in ICU: reproducibility of the National Healthcare Safety Network case definition in an Australian cohort of infection control professionalsAm J Infect Control200937864364819589619
   PubMed Web of Science ®Google Scholar
• Public Health Agency of CanadaPreventing infections associated with indwelling intravascular access devices. Canada Communicable Disease Report – Supplement [webpage on the Internet]Ottawa, ONPublic Health Agency of Canada1997 [updated November 8, 2002]. Available from: http://www.collectionscanada.gc.ca/webarchives/20071212094643/http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/97vol23/23s8/index.html#Accessed May 11, 2015
   Google Scholar